GSK Merger Helps CNS Breathe Easier About Breathe Right Patent Expiration
This article was originally published in The Tan Sheet
Executive Summary
CNS sees its proposed acquisition by Glaxo as an opportunity to protect the intellectual property rights and market share of its Breathe Right brand with the additional resources available to a larger company
You may also be interested in...
Acquisition Primes Airborne For Claims Overhaul
GF Capital Private Equity Fund is overhauling Airborne Inc. to steer the firm clear of the regulatory issues that have plagued it
Acquisition Primes Airborne For Claims Overhaul
GF Capital Private Equity Fund is overhauling Airborne Inc. to steer the firm clear of the regulatory issues that have plagued it
Acquisition Primes Airborne For Claims Overhaul
GF Capital Private Equity Fund is overhauling Airborne Inc. to steer the firm clear of the regulatory issues that have plagued it